AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37460263 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised prehabilitation programme
Number of subjects: 30
Study 37460276 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised nezulcitinib 3 mg
Number of subjects: 205
Study 37460276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 37460353 — intervention group
Group type: EXPERIMENTAL
Intervention: PHH-1V vaccine candidate
Number of subjects: 0
Study 37460370 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral argon plasma (NAP) at 100% coagulation mode, distance of 2-3 cm
Number of subjects: 10
Study 37460370 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral argon plasma (NAP)
Number of subjects: 10
Study 37460370 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral argon plasma (NAP) at energy 80% during 2-4 s at distance of 2 cm
Number of subjects: 10
Study 37460370 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral argon plasma (NAP) at energy 100% during 2-4 s at distance of 3 cm
Number of subjects: 10
Study 37460385 — intervention group
Group type: EXPERIMENTAL
Intervention: Trofinetide
Number of subjects: 0
Study 37460410 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation solution (TIS)
Number of subjects: 57
Study 37460410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 37460572 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium-68 labelled RGD PET/CT imaging
Number of subjects: 0
Study 37460603 — intervention group
Group type: EXPERIMENTAL
Intervention: Minzasolmin (UCB0599) administered at doses of 1 and 5 mg/kg intraperitoneally for three months.
Number of subjects: 0
Study 37460683 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term neoadjuvant endocrine therapy (NET) for 4 weeks (± 1 week)
Number of subjects: 37
Study 37460782 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab (IV administration)
Number of subjects: 5229
Study 37460782 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab (SC administration)
Number of subjects: 5229
Study 37460782 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab (IV and SC)
Number of subjects: 5229
Study 37460782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5229
Study 37461024 — intervention group
Group type: EXPERIMENTAL
Intervention: Low load blood flow restriction (LL-BFR) delivered twice daily at 20% 1-RM
Number of subjects: 150
Study 37461024 — intervention group
Group type: COMPARATOR
Intervention: Conventional heavier load resistance training (HL-RT) three-times per week at 70% 1-RM
Number of subjects: 150
Study 37461024 — intervention group
Group type: EXPERIMENTAL
Intervention: Low load blood flow restriction (LL-BFR)
Number of subjects: 150
Study 37461024 — intervention group
Group type: COMPARATOR
Intervention: Conventional heavier load resistance training (HL-RT)
Number of subjects: 150
Study 37461034 — intervention group
Group type: EXPERIMENTAL
Intervention: XLJDOD compound granule
Number of subjects: 730
Study 37461034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 730
Study 37461072 — intervention group
Group type: EXPERIMENTAL
Intervention: APP model of care (physiotherapist as first point of contact)
Number of subjects: 40
Study 37461089 — intervention group
Group type: EXPERIMENTAL
Intervention: SHEPP intervention (health education on healthy lifestyle and physical activity sessions for children, training of teachers, and awareness sessions for parents over 10 months)
Number of subjects: 1191
Study 37461089 — intervention group
Group type: EXPERIMENTAL
Intervention: SHEPP intervention
Number of subjects: 1191
Study 37461089 — intervention group
Group type: COMPARATOR
Intervention: Routine activity (control)
Number of subjects: 1191
Study 37461207 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A
Number of subjects: 0
Study 37461207 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B
Number of subjects: 0
Study 37461207 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 counts
Number of subjects: 0
Study 37461383 — intervention group
Group type: EXPERIMENTAL
Intervention: eMOMS (Electronic Monitoring of Mom's Schedule)
Number of subjects: 26
Study 37461450 — intervention group
Group type: EXPERIMENTAL
Intervention: GUÍA genetic counseling
Number of subjects: 551
Study 37461450 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) genetic counseling
Number of subjects: 551
Study 37461458 — intervention group
Group type: EXPERIMENTAL
Intervention: Comunică intervention (motivational interviewing and cognitive-behavioral therapy skills across eight live text-based counseling sessions)
Number of subjects: 305
Study 37461458 — intervention group
Group type: COMPARATOR
Intervention: Content-matched education attention control (eight time-matched educational modules)
Number of subjects: 305
Study 37461458 — intervention group
Group type: EXPERIMENTAL
Intervention: Comunică intervention
Number of subjects: 305
Study 37461538 — intervention group
Group type: EXPERIMENTAL
Intervention: Task shifting
Number of subjects: 7
Study 37461594 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice coaching intervention
Number of subjects: 0
Study 37461594 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 37461631 — intervention group
Group type: EXPERIMENTAL
Intervention: User-centred implementation strategy for tuberculosis contact investigation
Number of subjects: 0
Study 37461631 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard TB contact investigation)
Number of subjects: 0
Study 37461659 — intervention group
Group type: EXPERIMENTAL
Intervention: High bronchodilator response (BDR) group (N=277)
Number of subjects: 1134
Study 37461659 — intervention group
Group type: COMPARATOR
Intervention: Low bronchodilator response (BDR) group (N=278)
Number of subjects: 1134
Study 37461659 — intervention group
Group type: COMPARATOR
Intervention: LOCCS cohort (adult asthma cohort)
Number of subjects: 1134
Study 37461666 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurologic Dance Training (NDT-Tango)
Number of subjects: 0
Study 37461666 — intervention group
Group type: COMPARATOR
Intervention: Home Exercise (HEX)
Number of subjects: 0
Study 37461672 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer group intervention implemented by trained community volunteers
Number of subjects: 776
Study 37461672 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 776
Study 37461904 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention to support breastfeeding
Number of subjects: 44
Study 37461904 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 37461954 — intervention group
Group type: EXPERIMENTAL
Intervention: ozanimod 0.92 mg
Number of subjects: 247
Study 37461954 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 247
Study 37461956 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod 0.92 mg once daily
Number of subjects: 526
Study 37461956 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ozanimod treatment
Number of subjects: 526
Study 37461956 — intervention group
Group type: COMPARATOR
Intervention: Ozanimod induction followed by placebo maintenance
Number of subjects: 526
Study 37461956 — intervention group
Group type: COMPARATOR
Intervention: Continuous placebo treatment
Number of subjects: 526
Study 37461957 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod 0.23 mg on Day 1
Number of subjects: 496
Study 37461987 — intervention group
Group type: EXPERIMENTAL
Intervention: Whoop Strap 3.0 wearable technology for remote physiologic monitoring (RPM) used for 12 months.
Number of subjects: 7
Study 37461987 — intervention group
Group type: EXPERIMENTAL
Intervention: Whoop Strap 3.0 wearable technology for RPM.
Number of subjects: 7
Study 37462028 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT) plus best medical treatment (BMT)
Number of subjects: 450
Study 37462028 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (BMT) alone
Number of subjects: 450
Study 37462232 — intervention group
Group type: COMPARATOR
Intervention: Statins (simvastatin or atorvastatin) versus placebo
Number of subjects: 396
Study 37462232 — intervention group
Group type: COMPARATOR
Intervention: Statins plus metformin versus metformin alone
Number of subjects: 396
Study 37462232 — intervention group
Group type: COMPARATOR
Intervention: Statins plus oral contraceptive pill (OCP) versus OCP alone
Number of subjects: 396
Study 37462232 — intervention group
Group type: COMPARATOR
Intervention: Statins versus metformin
Number of subjects: 396
Study 37462232 — intervention group
Group type: COMPARATOR
Intervention: Statins versus oral contraceptive pill plus flutamide
Number of subjects: 396
Study 37462260 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth Mindful Movement and Breathing (eMMB)
Number of subjects: 0
Study 37462260 — intervention group
Group type: COMPARATOR
Intervention: Empathic Attention Control (AC)
Number of subjects: 0
Study 37462350 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with pain symptoms (colic, abdominal pain)
Number of subjects: 1852
Study 37462350 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with multimorbidity (common infections, eczema, food sensitivity)
Number of subjects: 1852
Study 37462350 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers of infants with colic and those visiting healthcare for pain
Number of subjects: 1852
Study 37462350 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with pain symptoms
Number of subjects: 1852
Study 37462350 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers of infants with colic and visiting healthcare
Number of subjects: 1852
Study 37462385 — intervention group
Group type: EXPERIMENTAL
Intervention: EMulate Therapeutics Voyager™ System
Number of subjects: 0
Study 37462430 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (0.03 U/kg IV bolus followed by 0.3 mU/kg/min infusion)
Number of subjects: 28
Study 37462471 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Stroke Unit (MSU) care
Number of subjects: 768
Study 37462471 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 768
Study 37462495 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PV)
Number of subjects: 0
Study 37462495 — intervention group
Group type: COMPARATOR
Intervention: Active control (anesthetic infiltration)
Number of subjects: 0
Study 37462600 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental formula for 6 consecutive weeks
Number of subjects: 15
Study 37462612 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioprosthetic surgical aortic valve intervention
Number of subjects: 421
Study 37462798 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based integrated model
Number of subjects: 140
Study 37462798 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiologist-interpreted differentiation model
Number of subjects: 140
Study 37462798 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated nomogram model
Number of subjects: 140
Study 37462799 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based computerized EF intervention (5 days/week, 30 min/day, total dose 30 hours)
Number of subjects: 60
Study 37462799 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 60
Study 37463012 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured foot examination form
Number of subjects: 8
Study 37463054 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Number of subjects: 448
Study 37463058 — intervention group
Group type: EXPERIMENTAL
Intervention: DC/MM fusion vaccination with GM-CSF and lenalidomide maintenance
Number of subjects: 203
Study 37463058 — intervention group
Group type: COMPARATOR
Intervention: Control (GM-CSF and lenalidomide or lenalidomide maintenance alone)
Number of subjects: 203
Study 37463058 — intervention group
Group type: EXPERIMENTAL
Intervention: DC/MM fusion vaccination
Number of subjects: 203
Study 37463240 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol-enhanced CMRA (3 mg/kg IV)
Number of subjects: 30
Study 37463309 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention telemedicine-based follow-up
Number of subjects: 0
Study 37463309 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up care
Number of subjects: 0
Study 37463344 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based light-intensity training with daily whey protein supplementation (LITW)
Number of subjects: 104
Study 37463344 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-based heavy resistance training with whey protein supplementation (HRTW)
Number of subjects: 104
Study 37463344 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily whey protein supplementation alone (WHEY)
Number of subjects: 104
Study 37463344 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training continuation (CONT)
Number of subjects: 104
Study 37463362 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal inoculation with commensal bacteria
Number of subjects: 31
Study 37463435 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel motorized spiral enteroscopy (NMSE)
Number of subjects: 72
Study 37463435 — intervention group
Group type: COMPARATOR
Intervention: Single-balloon enteroscopy (SBE)
Number of subjects: 72
Study 37463599 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use duodenoscope
Number of subjects: 551
Study 37463650 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole vaginal ovules for 5 days postoperatively with cefazolin 2 g intravenous single dose before surgery
Number of subjects: 574
Study 37463650 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaginal ovules for 5 days postoperatively with cefazolin 2 g intravenous single dose before surgery
Number of subjects: 574
Study 37463687 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic TDF for 6 months after completion of rituximab
Number of subjects: 90
Study 37463687 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic TDF for 12 months after completion of rituximab
Number of subjects: 90
Study 37463687 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic TDF for 6 months after completion of rituximab (PP analysis)
Number of subjects: 90
Study 37463687 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic TDF for 12 months after completion of rituximab (PP analysis)
Number of subjects: 90
Study 37463802 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline catheter (MC)
Number of subjects: 2000
Study 37463839 — intervention group
Group type: EXPERIMENTAL
Intervention: CogRx
Number of subjects: 39
Study 37463839 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 39
Study 37463839 — intervention group
Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 39
Study 37464064 — intervention group
Group type: EXPERIMENTAL
Intervention: Colovac+
Number of subjects: 25
Study 37464107 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Number of subjects: 0
Study 37464107 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous Drainage
Number of subjects: 0
Study 37464143 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy
Number of subjects: 225
Study 37464143 — intervention group
Group type: COMPARATOR
Intervention: Open gastrectomy
Number of subjects: 225
Study 37464228 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious game based on Gabor patches (study group)
Number of subjects: 60
Study 37464228 — intervention group
Group type: COMPARATOR
Intervention: Placebo software (placebo group)
Number of subjects: 60
Study 37464283 — intervention group
Group type: EXPERIMENTAL
Intervention: High voltage pulsed radiofrequency (PRF)
Number of subjects: 134
Study 37464283 — intervention group
Group type: COMPARATOR
Intervention: Nerve block with steroid and local anesthetic drugs
Number of subjects: 134
Study 37464283 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 134
Study 37464349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully immersive VR exergames (go/no-go punch game, go/no-go stepping game, number punch game), 10 sessions, 2-3 times a week, 30 min per session.
Number of subjects: 12
Study 37464349 — intervention group
Group type: EXPERIMENTAL
Intervention: VR exergames
Number of subjects: 12
Study 37464355 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stent (DES) implantation into nitrate-induced maximally dilated vessels
Number of subjects: 400
Study 37464355 — intervention group
Group type: COMPARATOR
Intervention: Conventional DES implantation
Number of subjects: 400
Study 37464378 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus CapeOx and bevacizumab
Number of subjects: 494
Study 37464378 — intervention group
Group type: COMPARATOR
Intervention: CapeOx and bevacizumab
Number of subjects: 494
Study 37464390 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual cueing using laser shoes
Number of subjects: 10
Study 37464404 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrain Manipulandum™ training
Number of subjects: 42
Study 37464404 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (CT)
Number of subjects: 42
Study 37464448 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery Protocol (ERP) implementation
Number of subjects: 18
Study 37464448 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-specific implementation report card
Number of subjects: 18
Study 37464448 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement with center-specific implementation teams
Number of subjects: 18
Study 37464448 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid-cycle feedback approach
Number of subjects: 18
Study 37464448 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-method evaluation approach
Number of subjects: 18
Study 37464551 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberty 640PM (EPS 2.0)
Number of subjects: 41
Study 37464862 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-Family Partnership (NFP)
Number of subjects: 739
Study 37464978 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR0302 8 mg once daily
Number of subjects: 24
Study 37464978 — intervention group
Group type: COMPARATOR
Intervention: Warfarin 5 mg (CYP2C9)
Number of subjects: 24
Study 37464978 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg (CYP2C19)
Number of subjects: 24
Study 37464978 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 15 mg (CYP3A4)
Number of subjects: 24
Study 37464978 — intervention group
Group type: COMPARATOR
Intervention: Repaglinide 0.5 mg (CYP2C8)
Number of subjects: 24
Study 37465323 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral roflumilast 500 μg once daily
Number of subjects: 46
Study 37465323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 37465396 — intervention group
Group type: EXPERIMENTAL
Intervention: PK-guided prophylaxis with rurioctocog alfa pegol targeting FVIII trough of 8-12%
Number of subjects: 0
Study 37465817 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1291583 1 mg once daily
Number of subjects: 240
Study 37465817 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1291583 2.5 mg once daily
Number of subjects: 240
Study 37465817 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1291583 5 mg once daily
Number of subjects: 240
Study 37465817 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily
Number of subjects: 240
Study 37465907 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2400 mg/day
Number of subjects: 42
Study 37465907 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 42
Study 37465924 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 0
Study 37465924 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 37465959 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task Augmented Reality Treatment (DART)
Number of subjects: 47
Study 37465959 — intervention group
Group type: COMPARATOR
Intervention: Traditional Dual-task Training (DTT)
Number of subjects: 47
Study 37465959 — intervention group
Group type: EXPERIMENTAL
Intervention: DART
Number of subjects: 47
Study 37465959 — intervention group
Group type: COMPARATOR
Intervention: Traditional DTT
Number of subjects: 47
Study 37465966 — intervention group
Group type: EXPERIMENTAL
Intervention: Wolff-Parkinson-White (WPW) pattern in neonates
Number of subjects: 17489
Study 37465966 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched 1:4 to WPW cases)
Number of subjects: 17489
Study 37465991 — intervention group
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin (MMAF-containing monoclonal antibody-drug conjugate)
Number of subjects: 0
Study 37465991 — intervention group
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Number of subjects: 0
Study 37465991 — intervention group
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin dosing regimens
Number of subjects: 0
Study 37466000 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA) 1 g over 10 minutes followed by 1 g over 8 hours
Number of subjects: 63
Study 37466000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 37466018 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise (NME) combined with back-care counseling
Number of subjects: 219
Study 37466018 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise (NME)
Number of subjects: 219
Study 37466018 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (NME + counseling)
Number of subjects: 219
Study 37466018 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 219
Study 37466110 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ondansetron (4 mg in 100 ml of 0.9% saline 1 hour before induction of anaesthesia)
Number of subjects: 121
Study 37466110 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative ondansetron (4 mg in 100 ml of 0.9% saline 30 min before end of surgery)
Number of subjects: 121
Study 37466110 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ondansetron
Number of subjects: 121
Study 37466110 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative ondansetron
Number of subjects: 121
Study 37466151 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (benazepril 10 mg or trandolapril 2 mg)
Number of subjects: 9379